Healthcare resource use and medical costs for the management of oesophageal cancer

摘要: Background: This study examined the interaction between natural history, current practice patterns in diagnosis, monitoring and treatment of oesophageal cancer, associated health resource utilization costs. Methods: A cost analysis a prospective population-based cohort 1100 patients with primary diagnosis cancer was performed using chart review from Australian Cancer Study Clinical Follow-Up Study. The enabled estimation healthcare resources costs 2009 euros by stage disease pathway. Results: Most (88·5 per cent) presented II, III or IV cancer; 61·1 cent (672 1100) were treated surgically. Overall mean €37 195 (median €29 114) for undergoing surgery €17 281 €13 066) those without surgery. Surgery contributed 66·4 total (mean €24 697 patient) surgical group. In non-surgical group, use chemotherapy more prevalent (81·9 patients) Other important determinants gastro-oesophageal junction tumours, location tumour stage. Mean monitored Barrett's oesophagus (7·3 lower, although about one-third still advanced-stage cancer. Conclusion: managing high dominated surgically Radiotherapy, subtype also important. Monitoring earlier-stage detection lower management costs, but potential net benefit surveillance strategies needs further investigation.